Journal of Neonatal Biology

Abstract

High Dose Octreotide for the Treatment of Chylothorax in Three Neonates

Makoto Saito, Tomohiro Kamoda, Daigo Kajikawa, Yayoi Miyazono, Yu Kanai, Satoshi Fujiyama, Ryoko Suzuki, Miho Takahashi-Igari, Yasuhisa Urita and Ryo Sumazaki

Chylothorax is an abnormal condition of lymphatic fluid collection in the　pleural space, and the somatostatin analog octreotide is thought to have a beneficial effect on chylothorax. However, the octreotide dosage and administration route for chylothorax have been inconsistent to date. We report three neonatal cases of persistent chylothorax successfully treated with high-dose octreotide infusion therapy (20 μg/kg/h). Case 1 was congenital chylothorax, Case 2 was secondary chylothorax after an operation for congenital diaphragmatic hernia, and Case 3 was chylothorax after a cardiac operation. In all cases, the chylothorax was not decreased by a low-dose octreotide infusion, but after a high-dose octreotide infusion, the chylothorax decreased and eventually vanished, with no side effects.

Conclusion: We suggest that the dose of octreotide in neonatal chylothorax can be safely increased to a maximum of 20 µg/kg/h.